Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05262270 · ClinicalTrials.gov registry record · Phase 2
Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 427
- Enrollment target
NCT05262270 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 427 participants.
The verdict
NCT05262270, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 427 participants
- Enrollment target
Study Summary
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).
Interventions
- DRUG Extended Release Buprenorphine
- DRUG Extended-Release Naltrexone
- DRUG Placebo (PLB) Injectable matched to XR-NTX
- DRUG Placebo (PLB) Injectable matched to XR-BUP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2025-07-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05262270
The ClinicalTrials.gov registry entry for NCT05262270 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 427 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Extended Release Buprenorphine is the first listed.
NCT05262270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05262270 about?
NCT05262270 is a clinical study titled "Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)". This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).
What is the current status of trial NCT05262270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 427 participants. The study started on 2023-04-18. Estimated completion is 2025-07-21.
What interventions are being tested in trial NCT05262270?
The interventions under investigation include: Extended Release Buprenorphine (DRUG), Extended-Release Naltrexone (DRUG), Placebo (PLB) Injectable matched to XR-NTX (DRUG), Placebo (PLB) Injectable matched to XR-BUP (DRUG).
Who is sponsoring clinical trial NCT05262270?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.